Announcement • Oct 27
Halberd Corporation Successfully Demonstrates Its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform Halberd Corporation announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to: Capture and process real-time behavioral data with professional-grade accuracy; Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics); Generate automated behavioral assessments and visualizations; Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms. Technology Validation Milestone: The successful demonstration represents a critical development milestone, confirming that: Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns. Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications. Announcement • May 28
Halberd Corporation & Athena Telemedicine Partnership, LLC Announce Clinical Study Updates Halberd Corporation in cooperation with Athena Telemedicine Partners, LLC, announced astounding clinical efficacy for patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. previously found that patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. The problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free. However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching. The company will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose. Athena GTX will be supplying wearable WatchDawg™? monitoring and cloud-based acquisition of data through partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. The company expects a full data presentation for a large and heretofore patient problem that was very difficult to manage. This will be one of two studies with which the company are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly. To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation. Announcement • Dec 03
Halberd Corporation Update on Watchdawg®? Ptsd Treatment Halberd Corporation previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January. Announcement • Oct 01
Halberd & Athena GTX Report Initial Success of WatchDawg®? PTSD Treatment Pilot Study Halberd Corporation released the results of the recently completed WatchDawg®? Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wear a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participants data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health. During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here. Announcement • Jul 24
Halberd Corporation's Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results Halberd Corporation announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX. Announcement • May 03
Halberd Announces Patented LDN+ Drug Has Begun Pre-Pilot Trials with Military Veterans Halberd Corporation announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks. The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation. Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies. 